Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Increase of Interferon Gamma Levels
研究概览
简要总结
Background:
Glioblastoma (GBM) brain tumors almost always return after treatment. When that happens the tumor can never completely be removed by surgery, so most people also receive drugs. Researchers want to see if combining the drugs nivolumab and BMS-986016 may help.
Objectives:
To study how nivolumab affects the brain s immune system in people who have had glioblastoma brain tumors return. To study how nivolumab and BMS-986016 affect brain tumors.
Eligibility:
Adults age 18 and older who have had a return of GBM
Design:
Participants will be screened with:
Medical history
Physical exam
Cheek swab
Heart, blood and urine tests
Chest x-ray
Magnetic resonance imaging (MRI) brain scan. Participants will lie on a table that slides in and out of a cylinder in a strong magnetic field. A contrast agent will be injected in an arm vein.
Participants will stay in the hospital. They will:
Have surgery. A tube will be inserted into the back. Brain tumor and bone marrow samples will be taken. Tubes will be inserted into the brain.
Have a computed tomography brain scan.
Stay in Intensive Care (ICU) 7 days. Fluid from the brain and back will be collected every few hours. In the ICU, participants will get nivolumab by IV for 30 minutes.
Have surgery to remove the tubes.
Have standard surgery to remove as much of the GBM as possible. Bone marrow will be removed.
After leaving the hospital, participants will have visits every 2 weeks to get the study drugs by IV and have physical exams and blood tests.
Participants will have a brain MRI once a month.
...
详细描述
Objective
This protocol is being performed to 1) characterize the clinical and 2) immunological response of patients with recurrent glioblastoma to treatment with Nivolumab, together with an anti-Lag-3 antibody, BMS-986016, and to evaluate the safety of brain tumor microdialysis in this patient population.
Study Population
10 patients (total, after replacement for any dropout), 18 years old and older with recurrence of glioblastoma after standard treatment of surgery, chemotherapy, and radiation.
Study Design
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Nivolumab and BMS-986016
Recurrent Glioblastoma patients
干预措施: Nivolumab (Drug)
Nivolumab and BMS-986016
Recurrent Glioblastoma patients
干预措施: BMS-986016 (Drug)
结局指标
主要结局
Increase of Interferon Gamma Levels
时间窗: Day 8
The proportion of patients that have a rise in interferon gamma levels within the tumor microenvironment of 4 pg/ml or higher before the first dose of Nivolumab as compared to the 5th day after treatment with Nivolumab.
Microdialysis Catheter
时间窗: Day 8
The number of patients with any adverse events that are directly attributable to placement of the microdialysis catheter. Specifically, intracranial hemorrhage, intracranial infection, wound infection, or new neurological deficit attributable to location of microdialysis catheter placement were to be captured
Drug Safety
时间窗: Day 8
The safety of the combination of nivolumab and BMS-986016 in recurrent glioblastoma patients
次要结局
未报告次要终点
